HCC1954 CDX Model

The HCC1954 cell line is derived from human HER2-positive breast cancer, a subtype characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2). This overexpression is often associated with aggressive tumor growth and a higher risk of recurrence. HCC1954 provides a crucial platform for elucidating the biology of HER2-positive tumors and for gauging the efficacy of targeted therapeutic strategies. This cell line exhibits many of the molecular features and genetic alterations typically observed in HER2-positive breast cancer patients, which enhances its applicability in preclinical research. Through in vitro and in vivo studies using HCC1954, insights can be gathered about the tumor’s growth dynamics, metastatic potential, and particularly its sensitivity and resistance mechanisms to HER2-targeted therapies. Researchers extensively utilize the HCC1954 model to understand the nuances of HER2-positive breast cancer and to test and refine therapeutic interventions, with a focus on optimizing anti-HER2 treatments.

Model Details

Cancer Location: Mammary Fat Pad
Cancer Type: HER2-Positive Breast Cancer
Model Name: HCC1954
Mouse Strain: NSG
Treatment Data Available: Chemotherapy (Trastuzumab)

HCC1954 Growth curves

HCC1954 CDX Model

Growth of orthotopic (MFP) HCC1954 in NSG mice (n=5)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.